Zhixin Haozheng (Shanghai) Pharmaceutical Technology

Zhixin Haozheng Regenerative Medicine, founded in 2019, focuses on the induction and differentiation of stem cells in vitro, aiming to regenerate tissues and organs. Led by Dr. Cheng Xin, a prominent researcher from the Center for Excellence in Molecular Cell Science, the company has developed a new human endoderm stem cell line with independent intellectual property rights. This line supports large-scale production of artificial islets and livers in vitro. The company operates in the regenerative medicine market, serving clients in the pharmaceutical and healthcare sectors. Its business model revolves around research and development, production, and clinical applications of cell-based therapies. Revenue is generated through the development and commercialization of stem cell-based products and therapies. The team comprises overseas returnees, foreign company executives, and professionals in cell drug applications, ensuring a comprehensive approach to innovation and application.

Keywords: stem cells, tissue regeneration, organ regeneration, in vitro, endoderm, drug development, cell therapy, artificial islets, artificial livers, healthcare.